To provide a critical contemporary review of daily PDE5-inhibitor (PDE5-I) use in urological and nonurological conditions.
PDE5-Is can be taken up to once a day. However, at present only tadalafil is approved for use in both erectile dysfunction (ED) and benign prostate hyperplasia (BPH) with lower urinary tract symptoms (LUTS). Evolving research in penile rehabilitation, Peyronie's disease, male infertility, pulmonary arterial hypertension, muscular dystrophy and Raynaud's phenomenon shows these therapeutic areas may also benefit from PDE5i therapy. This review examines the role of chronic PDE5 inhibition in ED, BPH-LUTS and other therapeutic targets which may shape our clinical practice in the years to come.
Written by:
Lee KC, Brock GB. Are you the author?
Department of Urology, National University Hospital, 1E Kent Ridge Road, NUHS Tower Block, Level 8, Singapore, 119228, Singapore.
Reference: Curr Urol Rep. 2013 Jun 18. Epub ahead of print.
doi: 10.1007/s11934-013-0342-9
PubMed Abstract
PMID: 23775467
UroToday.com Erectile Dysfunction Section
